Search PubMed⌕ Search

Biomedical subjects

M V Calvo

Publications and source records attributed to M V Calvo.

27 records · Page 2Linked to original sources
PubMed1985

Pharmacokinetics and initial distribution of a new neuroleptic agent picobenzide (M-14012-4).

The pharmacokinetics of picobenzide was studied in 14 adult patients undergoing neuroleptoanalgesic sessions. The dose of picobenzide administered was 10 mg/kg by i.v. injection. The pharmacokinetic parameters obtained revealed a good distribution capacity with an average value of the apparent distribution volume at steady state of 28.29 +/- 4.98 1. The drug was also seen to be eliminated rapidly from the organism with an average value of the serum half-life of 2.05 +/- 0.42 h. The determination of the initial distribution kinetics of picobenzide shows that the use of a conventional kinetic model induces an overestimation of the initial distribution volume in turn caused by an underestimation of the initial serum concentration.

Adult↗
PubMed1985

Results of treatment with sodium sulbenicillin in thirty elderly patients with acute bronchopulmonary infection.

Thirty elderly patients with acute bronchopulmonary infections were treated with intravenous sodium sulbenicillin for up to 20 days at a dose of 4-6 g/day. Clinical results were excellent in 19 cases and good in 10 cases. In one case treatment had to be discontinued due to a dermal side-effect. It is concluded that sulbenicillin is a useful therapy for acute bronchopulmonary infections in the elderly.

Aged↗
PubMed1981

Pharmacokinetics of naproxen in patients with hypoproteinemia.

The pharmacokinetics of naproxen were studied in nine patients with hypoproteinemia with total protein counts between 4.5 and 5.5 g/100 ml. All patients received an oral dose of 250 mg naproxen. Plasma concentrations of the drug were determined spectrofluorometrically. In this kind of patient the drug follows a single-compartment kinetic model. The average value of Cmax is 18.55 +/- 7.05 micrograms/ml, far lower than that obtained in healthy volunteers. A linear relationship is established between the values of Cmax and the total protein concentration. The plasma protein binding is not modified in this kind of patient. The bioavailability compared with healthy volunteers receiving the same dose was 45.55%.

Adult↗
PubMed1980

Naproxen disposition in hepatic and biliary disorders.

The pharmacokinetics of Naproxen have been studied in 11 patients diagnosed with various hepatic and biliary disorders after oral administration of a single dose of 250 mg of the drug. The drug is seen to follow an open two-compartment model. In relation to the values obtained from healthy volunteers, it may be seen that in these patients there are modifications in the absorption, distribution and elimination of the drug. In certain of the patients with cholestasis, a significant delay in absorption may be observed. In most of the patients studied, elimination is clearly diminished due to a decrease in the capacity to biotransform the drug within the organism. In healthy volunteers, the plasma half-life of the beta-phase has an average value of 14.14 hrs while in patients it reaches a value of 20.36 hrs.

Cholestasis↗
PubMed1979

Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy.

The pharmacokinetics of Naproxen administered as a single oral dose of 250 mg, have been determined in 7 healthy volunteers and 9 patients who had been diagnosed as suffering from diabetes mellitus with varying degrees of angiopathy. A two-compartment model was used to describe the biphasic decline in serum concentrations and to calculate the amount of drug in the central and peripheral compartments. In healthy volunteers the following values were obtained for various pharmacokinetic parameters: tmax = 2 hr; Cmax = 52.63 micrograms/ml; Ka = 1.893 hr-1; alpha = 0.393 hr-1; beta = 0.049 hr-1; K12 = 0.147 hr-1; K21 = 0.198 hr-1; K13 = 0.097 hr-1. In patients with severe diabetic microangiopathy, a decrease may be seen in the fraction of the dose absorbed shown by a decrease in the Cmax and the (AUC) 0--8 hr. The glomerular impairment of some patients leads to a decrease in the elimination constant.

Adult↗
PubMedDate not supplied

Interaction of naproxen with cholestyramine.

'In vitro' and 'in vivo' studies were used to determine the interaction of naproxen, an anti-inflammatory agent, and cholestyramine, a hypocholesterolemic substance. Cholestyramine shows a marked affinity for naproxen and the intensity of this is governed by the pH values. The maximum amount of naproxen adsorbed by the resin is close to 2.2 mM g-1. The pharmacokinetics of naproxen was studied in eight healthy volunteers after concurrent oral administration in a single dose of 250 mg of naproxen and 4 g of cholestyramine. The resin causes an important delay in the incorporation of naproxen into the systemic circulation, though no significant modifications are seen to take place in any other pharmacokinetic parameters of the drug.

Adsorption↗
PubMedDate not supplied

[Cost-effectiveness of individualized enteral nutrition by a nutrition support team in laryngectomized cancer patients].

The purpose of this study was to evaluate the effectiveness of a Nutritional Support Team (NST) in the control and follow-up of enteral nutrition (EN) in patients subjected to laryngectomy as a result of neoplasia. The study was performed on two groups of patients (A and B) who had been admitted into the Otorhinolaryngological Department, and who required EN by nasogastric tube during the postoperative period. Group A consisted of 20 patients in whom EN was based on standard guidelines, with a daily intake of 11.1 g of Nitrogen and 2.000 kcals. Group B included 23 patients who received EN individually, using NST with a daily intake of Nitrogen of between 8 and 21 g, and energy intake of between 2.000 and 3.000 kcals. The total cost of nutrition was calculated using the following partial costs: diet, administration, laboratory analysis and NST head responsible for follow-up of Group B. Individualized EN was more effective in nutritional terms than a standard diet in all patients. Using this form of treatment, positive Nitrogen balance were achieved, levels of seric albumin were maintained as well as weight, and complications were reduced. The average cost of nutrition per patient in Group B was 46.258 pesetas and in Group A, 43.963 pesetas. However, in the latter Group, there was an average additional weight loss of 4 kg per patient, and an increase in cost effectiveness ratio of 573 pesetas in weight gained in Group B compared to Group A.

Adult↗